Trial reportJAMA2020
Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial.
Trial report in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 10 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Deprescribing preventive medications in older adults with advanced frailty, dementia, or limited life expectancy: a systematic review and meta-analysis.BMC geriatrics · 2026Pooled it
- Deprescribing antihypertensive medications in older people: a systematic review and a meta-analysis.BMC geriatrics · 2026Pooled it
- Withdrawal of antihypertensive drugs in older people.The Cochrane database of systematic reviews · 2025Pooled it
- Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review.Journal of general internal medicine · 2024Pooled it
- Hypertension Treatment in Frail Older Adults: A Systematic Review and Appraisal of Guidelines.Drugs & aging · 2023Pooled it
- Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis.Age and ageing · 2023Pooled it
- The influence of hypertension management on frailty prevention among older persons aged 65 and over: a systematic review.Aging clinical and experimental research · 2022Pooled it
- Medication reviews and deprescribing as a single intervention in falls prevention: a systematic review and meta-analysis.Age and ageing · 2022Pooled it
- Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials.BMC family practice · 2021Pooled it
- Association between antihypertensive treatment and adverse events: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2021Pooled it
- Pharmacist-led deprescribing of cardiovascular and diabetes medication within a clinical medication review: the LeMON study (Less Medicines in Older Patients in the Netherlands), a cluster randomized controlled trial.International journal of clinical pharmacy · 2025Trial
- Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial.The lancet. Healthy longevity · 2024Trial
- Trial
- Efficacy of decentralised home-based antihypertensive treatment in older adults with multimorbidity and polypharmacy (ATEMPT): an open-label randomised controlled pilot trial.The lancet. Healthy longevity · 2024Trial
- Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial.Drugs & aging · 2024Trial
- Cost-Effectiveness of Antihypertensive Deprescribing in Primary Care: a Markov Modelling Study Using Data From the OPTiMISE Trial.Hypertension (Dallas, Tex. : 1979) · 2022Trial
- Effects of Antihypertensive Deprescribing Strategies on Blood Pressure, Adverse Events, and Orthostatic Symptoms in Older Adults: Results From TONE.American journal of hypertension · 2022Trial
- Long-Term Persistence and Treatment Changes of Antihypertensive Therapy: A 5-Year Cohort Study.Basic & clinical pharmacology & toxicology · 2026Article
- Appropriateness over Numbers: Pharmacological Burden and Scalable Medication Review in Older Adults.Geriatrics (Basel, Switzerland) · 2026Review
- Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults.Journal of the American Geriatrics Society · 2026Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
Abstract
Importance: Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and multimorbidity when the benefits of continued treatment may not outweigh the harms. Objective: This study aimed to establish whether antihypertensive medication reduction is possible without significant changes in systolic blood pressure control or adverse events during 12-week follow-up. Design, Setting, and Participants: The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites in England. Participants, whose primary care physician considered them appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2 antihypertensive medications were included. Participants enrolled between April 2017 and September 2018 and underwent follow-up until January 2019. Interventions: Participants were randomized (1:1 ratio) to a strategy of antihypertensive medication reduction (removal of 1 drug [intervention], n = 282) or usual care (control, n = 287), in which no medication changes were mandated. Main Outcomes and Measures: The primary outcome was systolic blood pressure lower than 150 mm Hg at 12-week follow-up. The prespecified noninferiority margin was a relative risk (RR) of 0.90. Secondary outcomes included the proportion of participants maintaining medication reduction and differences in blood pressure, frailty, quality of life, adverse effects, and serious adverse events. Results: Among 569 patients randomized (mean age, 84.8 years; 276 [48.5%] women; median of 2 antihypertensive medications prescribed at baseline), 534 (93.8%) completed the trial. Overall, 229 (86.4%) patients in the intervention group and 236 (87.7%) patients in the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks (adjusted RR, 0.98 [97.5% 1-sided CI, 0.92 to ∞]). Of 7 prespecified secondary end points, 5 showed no significant difference. Medication reduction was sustained in 187 (66.3%) participants at 12 weeks. Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.8 mm Hg) higher in the intervention group compared with the control group. Twelve (4.3%) participants in the intervention group and 7 (2.4%) in the control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]). Conclusions and Relevance: Among older patients treated with multiple antihypertensive medications, a strategy of medication reduction, compared with usual care, was noninferior with regard to systolic blood pressure control at 12 weeks. The findings suggest antihypertensive medication reduction in some older patients with hypertension is not associated with substantial change in blood pressure control, although further research is needed to understand long-term clinical outcomes. Trial Registration: EudraCT Identifier: 2016-004236-38; ISRCTN identifier: 97503221.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.